ライフサイエンスコーパス: acute liver failure

1 damage, a paradigm for glutathione-mediated acute liver failure.

2 es of drug induced liver injury resulting in acute liver failure.

3 rum cytokine assays 12 h after initiation of acute liver failure.

4 r data in consecutive patients admitted with acute liver failure.

5 ric patients with end-stage liver disease or acute liver failure.

6 Keratin variants may predict outcome of acute liver failure.

7 Group 3 animals declined rapidly, with acute liver failure.

8 gan dysfunction and outcome in patients with acute liver failure.

9 dysfunction syndrome and improve outcome in acute liver failure.

10 ated injury and systemic inflammation during acute liver failure.

11 n toxicity among subjects with indeterminate acute liver failure.

12 s may be an effective treatment modality for acute liver failure.

13 ver injury (DILI), chronic liver disease, or acute liver failure.

14 ty factor shown to predispose to HAV-induced acute liver failure.

15 r disease which in some instances has led to acute liver failure.

16 complications independently associated with acute liver failure.

17 enerative process in liver diseases, such as acute liver failure.

18 efit patients with non-acetaminophen-related acute liver failure.

19 s with early stage non-acetaminophen-related acute liver failure.

20 minophen (APAP) overdose is a major cause of acute liver failure.

21 bclinical cardiac injury might also occur in acute liver failure.

22 tions that lead to generalized infection and acute liver failure.

23 siRNA resulted in the early onset of lethal, acute liver failure.

24 e intensive care management of patients with acute liver failure.

25 y been reported for adults and children with acute liver failure.

26 d to be associated with severe hepatitis and acute liver failure.

27 thways to disease diagnosis and treatment of acute liver failure.

28 ut difficult aspects of the clinical care of acute liver failure.

29 s are some of the newly identified causes of acute liver failure.

30 ypic expression of disease and management of acute liver failure.

31 postmortem samples from individuals without acute liver failure.

32 terified carnitine profiles in children with acute liver failure.

33 therapeutic option to treat posthepatectomy acute liver failure.

34 idation may predispose to a worse outcome in acute liver failure.

35 tion during follow-up, and 1 of them died of acute liver failure.

36 d, multicenter trial in patients with severe acute liver failure.

37 nts with liver-based metabolic disorders and acute liver failure.

38 ining diet before azoxymethane (AOM)-induced acute liver failure.

39 hat can lead to herpes simplex virus-induced acute liver failure.

40 making in patients with paracetamol-induced acute liver failure.

41 cids in the neurological complications after acute liver failure.

42 etaminophen overdose is the leading cause of acute liver failure.

43 or the importance of these variants in human acute liver failure.

44 for regenerative therapies for APAP-induced acute liver failure.

45 es, hepatitis E may lead to life-threatening acute liver failure.

46 side analogue (fialuridine [FIAU]) developed acute liver failure.

47 ith well-characterized acetaminophen-related acute liver failure, 10 patients with ALF owing to other

48 ytokine assays showed pronounced features of acute liver failure 12 h after application of acetaminop

49 Of 165 children admitted with pediatric acute liver failure, 136 met the inclusion criteria and

50 were 11 catastrophic events (early deaths or acute liver failures; 2.9 per 1000; 95% CI, 1.5-5.1); si

51 In patients with acetaminophen-induced acute liver failure, a low serum level of CSF1 was assoc

52 Acetaminophen-induced acute liver failure (AALF) is associated with innate imm

53 Acetaminophen-induced acute liver failure (AALF) is characterized both by acti

54 xicity accounts for 41%; among children with acute liver failure, acetaminophen was the second most c

55 roup registry of more than 700 patients with acute liver failure across the United States implicates

56 ths post-transplantation was associated with acute liver failure (adjusted odds ratio 1.61), donor ag

57 from 78 patients with acetaminophen-induced acute liver failure admitted to the Royal Infirmary Edin

58 on in alcoholic liver disease (8.3-24.0) and acute liver failure (ALF) (5.9-7.6).

59 a concentrations are common in patients with acute liver failure (ALF) and are associated with hepati

60 ival was also analyzed by underlying disease-acute liver failure (ALF) and chronic liver failure.

61 eration, overwhelming liver damage can cause acute liver failure (ALF) and death without emergent liv

62 hose adults with nonacetaminophen (non-APAP) acute liver failure (ALF) and grade 1-2 hepatic encephal

63 Mechanisms of brain edema in acute liver failure (ALF) are not completely understood.

64 Twelve percent of all acute liver failure (ALF) cases are of unknown origin, o

65 yzed 217 serum samples from 69 patients with acute liver failure (ALF) collected up to 24 months post

66 About 20% of patients with acute liver failure (ALF) die from increased intracrania

67 Acute liver failure (ALF) due to drug-induced liver inju

68 Acute liver failure (ALF) due to hepatitis A virus (HAV)

69 Acute liver failure (ALF) due to Wilson disease (WD) is

70 BACKGROUND & AIMS: Patients with acute liver failure (ALF) have defects in innate immune

71 BACKGROUND DATA: Patients with severe acute liver failure (ALF) have extreme physiologic dysfu

72 BACKGROUND & AIMS: Patients with acute liver failure (ALF) have high mortality and freque

73 paracetamol) poisoning is a leading cause of acute liver failure (ALF) in humans and induces hepatocy

74 Acute liver failure (ALF) in infancy and childhood is a

75 virus (HEV) infection is a leading cause of acute liver failure (ALF) in many developing countries,

76 ification accuracy of an e-Nose in detecting acute liver failure (ALF) in rats.

77 inophen toxicity is the most common cause of acute liver failure (ALF) in the United States and Great

78 Medications are a major cause of acute liver failure (ALF) in the United States, but no p

79 acetaminophen (APAP) is the leading cause of acute liver failure (ALF) in the United States.

80 Acute liver failure (ALF) induced by diffuse metastatic

81 Acute liver failure (ALF) is a devastating clinical synd

82 Acute liver failure (ALF) is a devastating syndrome affl

83 Hepatitis B virus (HBV)-associated acute liver failure (ALF) is a dramatic clinical syndrom

84 Acute liver failure (ALF) is a prototypical syndrome of

85 Acute liver failure (ALF) is a rare but challenging clin

86 Acute liver failure (ALF) is a rare condition characteri

87 Acute liver failure (ALF) is a rare syndrome of severe,

88 Acute liver failure (ALF) is associated with massive hep

89 Acetaminophen (APAP)-induced acute liver failure (ALF) is associated with significant

90 ying autoimmune hepatitis as the etiology of acute liver failure (ALF) is potentially important, beca

91 Mortality of patients with acute liver failure (ALF) is still unacceptably high.

92 Drug-induced and indeterminate acute liver failure (ALF) might be due to an autoimmune-

93 type is the most suitable source of CBTs for acute liver failure (ALF) or chronic liver failure (CLF)

94 adducts might improve diagnostic accuracy in acute liver failure (ALF) patients.

95 the central nervous system in patients with acute liver failure (ALF) present unique challenges in t

96 develop severe acute liver injury (sALI) or acute liver failure (ALF) remain little known.

97 Acute liver failure (ALF) remains a disease with poor pa

98 Brain edema in acute liver failure (ALF) remains lethal.

99 Acute liver failure (ALF) represents a life-threatening

100 eptibility to developing sepsis is common in acute liver failure (ALF) resulting in tissue damage and

101 Acute liver failure (ALF) shares striking similarities w

102 om acetaminophen (APAP, paracetamol)-induced acute liver failure (ALF) showed significant differences

103 ride (LPS) and concanavalin A (ConA)-induced acute liver failure (ALF), but the mechanism by which FK

104 injury or arrhythmias have been reported in acute liver failure (ALF), overall, the heart is conside

105 hypertension and mortality in patients with acute liver failure (ALF).

106 Acetaminophen toxicity is a leading cause of acute liver failure (ALF).

107 gnized and potentially fatal complication of acute liver failure (ALF).

108 l liver support device, may be beneficial in acute liver failure (ALF).

109 sure are potentially lethal complications of acute liver failure (ALF).

110 lantation currently exists for patients with acute liver failure (ALF).

111 aminophen hepatotoxicity frequently leads to acute liver failure (ALF).

112 injury models in mice, and in patients with acute liver failure (ALF).

113 ten serious in pregnancy and could result in acute liver failure (ALF).

114 action, is used widely to determine risk for acute liver failure (ALF).

115 minophen (APAP) overdose is a major cause of acute liver failure (ALF).

116 asma of patients with acute liver injury and acute liver failure (ALI/ALF).

117 ucing intracranial pressure in patients with acute liver failure and cerebral edema.

118 n of AAT can be a promising therapy to treat acute liver failure and clinical studies to explore this

119 on in 24 patients with acetaminophen-induced acute liver failure and compared with 10 healthy control

120 tation into mice with concanavalin-A-induced acute liver failure and fatal metabolic liver disease du

121 strophic consequences to the graft including acute liver failure and graft loss.

122 Acetaminophen (APAP) overdose results in acute liver failure and has limited treatment options.

123 e most common complications are secondary to acute liver failure and include severe coagulopathy, enc

124 is the most frequent precipitating cause of acute liver failure and liver transplant, but contempora

125 nificantly elevated in acetaminophen-induced acute liver failure and non-acetaminophen induced acute

126 onic hyperammonemia animal models, including acute liver failure and ornithine transcarbamylase defic

127 otoxin) is implicated in the pathogenesis of acute liver failure and several chronic inflammatory liv

128 inophen overdose is the most common cause of acute liver failure and the leading cause of chronic liv

129 ver disease treated (metabolic, chronic, and acute liver failure), and these are accompanied by semin

130 enol [APAP]) is one of the leading causes of acute liver failure, and APAP hepatotoxicity is associat

131 in three distinct models of TNFalpha-induced acute liver failure, and cells from these mice do not di

132 Hypoxemia is a feared complication of acute liver failure, and high oxygen requirements will f

133 liver disease remains an important cause of acute liver failure, and research efforts by the Nationa

134 is responsible for the majority of cases of acute liver failure, and the presence of co-existing chr

135 Young children with rapid onset acute liver failure are a high-risk subpopulation.

136 HSV-1 generalized infections and subsequent acute liver failure are less well understood.

137 me of acute respiratory distress syndrome in acute liver failure are scant and hypoxemia being a comm

138 ients with liver-based metabolic disease and acute liver failure as a potential alternative to liver

139 Given the apparent increasing incidence of acute liver failure attributable to APAP in the US, addi

140 ceptor 9 expression in acetaminophen-induced acute liver failure being mediated both by circulating e

141 r the management of individual patients with acute liver failure, but also to improve the uniformity

142 Treatment of acute liver failure by cell transplantation is hindered

143 d intracranial hypertension in patients with acute liver failure by decreasing splanchnic ammonia pro

144 Acute liver failure can be associated with rapidly progr

145 Drug-induced acute liver failure can be caused by many drugs routinel

146 Life-threatening acute liver failure can be triggered by a variety of fac

147 n confirm that of the approximately 1600 new acute liver failure cases annually, acetaminophen hepato

148 We describe a case of acute liver failure caused by echovirus 25 (E25) in a pr

149 ine seems to be beneficial for patients with acute liver failure caused by medications or herbal agen

150 lase concentrations in acetaminophen-induced acute liver failure compared with controls (p < 0.05).

151 d in all patients with acetaminophen-induced acute liver failure compared with healthy controls (p <

152 or autoimmune hepatitis) or patients without acute liver failure (controls) collected from a DILI Bio

153 osition as the leading cause of drug-induced acute liver failure, currently accounting for nearly 50%

154 atients with life-threatening liver disease (acute liver failure, decompensated cirrhosis, or severe

155 isting hepatocytes, liver repopulation after acute liver failure depends on the differentiation of pr

156 tracranial pressure monitor in acetaminophen acute liver failure did not confer a significant 21-day

157 commonly available on admission in cases of acute liver failure due to APAP overdose and should be v

158 outcome in a well-established mouse model of acute liver failure during septic shock.

159 izations, and an estimated 458 deaths due to acute liver failure each year.

160 nd stabilize the lost metabolic function for acute liver failure, end-stage and congenital liver dise

161 In these regions it is an important cause of acute liver failure, especially in pregnant women who ha

162 at Angiopoietin-2 protein was upregulated in acute liver failure explants compared with matched liver

163 imate the risk of perioperative mortality or acute liver failure for live liver donors in the United

164 Acute liver failure from primary hepatic lymphoma (PHL)

165 osing cholangitis, neonatal hemochromatosis, acute liver failure (from the Pediatric Acute Liver Fail

166 brain herniation are major complications of acute liver failure (fulminant hepatic failure) and a ma

167 identify information related to drug-induced acute liver failure, gastrointestinal hypomotility, cons

168 aware of common drug causes of drug-induced acute liver failure, gastrointestinal hypomotility, cons

169 veloped severe laboratory abnormalities, and acute liver failure has been reported (Table ).

170 Hepatitis B virus (HBV)-related acute liver failure (HBV-ALF) may occur after acute HBV

171 nophen is the single most important cause of acute liver failure here and abroad, such efforts to lim

172 ing 30 Argentinean patients with HAV-induced acute liver failure in a case-control, cross-sectional,

173 18-associated severe systemic infection and acute liver failure in an adult hematopoietic stem cell

174 The etiology of acute liver failure in children is unknown in a large nu

175 Acute liver failure in children was shown to differ in s

176 ed model of lipopolysaccharide (LPS)-induced acute liver failure in D-galactosamine (GalN)-sensitized

177 es, who presented with recurrent episodes of acute liver failure in early infancy and are affected by

178 Acetaminophen (APAP) overdose causes acute liver failure in humans and rodents due in part to

179 Because it is among the common causes of acute liver failure in intensive care units and in light

180 ay represent a therapeutic strategy to treat acute liver failure in mice.

181 that ameliorates the effects of APAP-induced acute liver failure in the mouse and therefore may provi

182 rdose is a major cause of hepatotoxicity and acute liver failure in the U.S., but the pathophysiology

183 inophen toxicity is the most common cause of acute liver failure in the United States and Europe.

184 erdose is one of the most frequent causes of acute liver failure in the United States and is primaril

185 ry (DILI) is among the most common causes of acute liver failure in the United States, accounting for

186 (APAP) overdose is the predominant cause of acute liver failure in the United States.

187 ylenol, is the leading cause of drug-induced acute liver failure in the United States.

188 ity is the most common drug-induced cause of acute liver failure in the United States.

189 overdose is a leading cause of drug-related acute liver failure in the United States.

190 n hepatotoxicity far exceeds other causes of acute liver failure in the United States.

191 nophen continuing to be the leading cause of acute liver failure in the USA.

192 acetaminophen (APAP) is the leading cause of acute liver failure in the Western world.

193 terile cell death and the commonest cause of acute liver failure in the western world.

194 liver injury and the most frequent cause of acute liver failure in the Western world.

195 acetaminophen poisoning in nearly 50% of all acute liver failure in this country.

196 phen (APAP) overdose is the leading cause of acute liver failure in Western countries.

197 APAP) overdose is the most frequent cause of acute liver failure in young adults in the United States

198 y is associated with modulating pathology in acute liver failure, in liver regeneration, and in the m

199 Acute liver failure induced by hepatotoxic drugs results

200 Acute liver failure initiates a sterile inflammatory res

201 ntracranial pressure monitored patients with acute liver failure, intracranial hypertension is common

202 process that occurs after liver injury, but acute liver failure is a complex and fatal disease which

203 Acute liver failure is a potentially devastating clinica

204 Acute liver failure is a rare disorder with high mortali

205 The incidence of hepatitis C and acute liver failure is also increased.

206 ized, and its pathogenesis in the context of acute liver failure is unclear.

207 mine-induced osmotic swelling, especially in acute liver failure, is a contributing factor: the osmot

208 rtality benefit, whereas in nonacetaminophen acute liver failure, it may be associated with worse out

209 s in patients with WD who have progressed to acute liver failure, leaving liver transplantation as th

210 olangitis, nonalcoholic fatty liver disease, acute liver failure, liver transplantation, neonatal hem

211 Patients with paracetamol-induced acute liver failure managed at intensive care units in t

212 of therapeutic hypothermia in patients with acute liver failure, multicenter, randomized, controlled

213 luded patients with nonacetaminophen-induced acute liver failure (n = 13), nonhepatic multiple organ

214 irrhosis without decompensation (n = 17), or acute liver failure (n = 23).

215 Acute liver failure not caused by paracetamol was associ

216 compartment syndrome must be suspected when acute liver failure occurs in patients with subcapsular

217 Intracranial hypertension in patients with acute liver failure often can be temporarily controlled

218 were measured in sera from 37 patients with acute liver failure on admission and from 20 healthy con

219 ssion was increased in acetaminophen-induced acute liver failure on day 1 compared with healthy contr

220 all patients recovered without experiencing acute liver failure or chronic liver injury.

221 vides an excellent outcome for patients with acute liver failure or complications of end-stage liver

222 te attack in acute intermittent porphyria or acute liver failure or end-stage chronic liver disease i

223 Liver failure, whether arising directly from acute liver failure or from decompensated chronic liver

224 rated in patients with acetaminophen-induced acute liver failure (p = 0.042) at the time of liver tra

225 Pediatric acute liver failure (PALF) is a potentially devastating

226 y between children and adults, the Pediatric Acute Liver Failure (PALF) Study Group evaluated NAC in

227 cranial pressure monitoring in patients with acute liver failure, patient selection and ancillary ass

228 l, pulmonary, and endocrine complications of acute liver failure patients are provided, including the

229 liver failure and non-acetaminophen induced acute liver failure patients compared with multiple orga

230 Acute liver failure patients receiving mechanical ventil

231 human hepatocytes have been used to sustain acute liver failure patients until liver transplantation

232 Two hundred acute liver failure patients were admitted during the st

233 ting but as yet unproven means of supporting acute liver failure patients with advanced encephalopath

234 In a prospective, double-blind trial, acute liver failure patients without clinical or histori

235 Similarly, Phase I trials of the BAL in acute liver failure patients yielded promising results.

236 ergent practices and a paucity of studies in acute liver failure patients, additional information was

237 nagement of intracranial hypertension in non-acute liver failure patients.

238 early phases of human acetaminophen-induced acute liver failure, peaking on day 1 of hospital admiss

239 amine the influence of acetaminophen-induced acute liver failure plasma and endogenous DNA on Toll-li

240 ls were incubated with acetaminophen-induced acute liver failure plasma with and without deoxyribonuc

241 upon stimulation with acetaminophen-induced acute liver failure plasma, which was abrogated by prein

242 In drug-induced acute liver failure, plasma levels correlate with outcom

243 rough the critical period for survival after acute liver failure, providing promising clues of integr

244 Few conditions are known to cause recurrent acute liver failure (RALF), and in about 50% of cases, t

245 Acute liver failure remains a critical clinical conditio

246 ause of liver injury in 14% of patients with acute liver failure remains unknown (indeterminate).

247 tive or detrimental in acetaminophen-induced acute liver failure remains unknown.

248 liver transplantation in paracetamol-induced acute liver failure require re-evaluation.

249 Patients with acute liver failure should be maintained in a mildly hyp

250 plantation of hiPSC-EB-HLC in a rat model of acute liver failure significantly prolonged the mean sur

251 rospectively collected cases of all forms of acute liver failure since 1998.

252 only measured clinical variables (called the Acute Liver Failure Study Group [ALFSG] index) and compa

253 minate, and drug-induced ALF patients in the Acute Liver Failure Study Group from 1998-2007.

254 males), who met the criteria defined by the "Acute Liver Failure Study Group Germany".

255 The Acute Liver Failure Study Group has prospectively collec

256 which to study acute liver failure, the U.S. Acute Liver Failure Study Group has sought to standardiz

257 late, 0.604 alone, 0.797 with FABP1) and the Acute Liver Failure Study Group prognostic index (early,

258 sorbent assay with clinical data from the US Acute Liver Failure Study Group registry (1998-2014).

259 Data from the U.S. Acute Liver Failure Study Group registry of more than 70

260 ions, sera from 110 subjects enrolled in the Acute Liver Failure Study Group registry with indetermin

261 measured in 187 patients enrolled in the US Acute Liver Failure Study Group registry, and correlated

262 m samples of 681 adults enrolled in the U.S. Acute Liver Failure Study Group were tested for anti-HEV

263 sis, acute liver failure (from the Pediatric Acute Liver Failure Study Group), and liver transplantat

264 Acute Liver Failure Study Group.

265 ccording to the latest figures from the U.S. Acute Liver Failure Study Group.

266 In acute liver failure, subclinical myocardial injury appea

267 Well-established preclinical models of acute liver failure such as the Jo2 FAS/CD95 activating

268 s an infrequent but well-recognized cause of acute liver failure that can now be effectively prevente

269 potentially life-threatening complication of acute liver failure, the syndrome of abrupt loss of live

270 ovide a uniform platform from which to study acute liver failure, the U.S. Acute Liver Failure Study

271 sity for patients with acetaminophen-induced acute liver failure to develop sepsis, which may culmina

272 agement of patients with paracetamol-induced acute liver failure to identify those needing emergency

273 ly in critically ill children with pediatric acute liver failure to provide stability and bridge to t

274 nin I levels may be helpful in patients with acute liver failure, to detect unrecognized myocardial d

275 , aripiprazole for MI, and telithromycin for acute liver failure) using Medicaid Analytic eXtracts (f

276 with neostigmine diminishes liver damage in acute liver failure via the cholinergic anti-inflammator

277 Median age of patients with acute liver failure was 34 yrs, 29 were female, and 21 d

278 The ensuing acute liver failure was characterized by serological, hi

279 Acute liver failure was induced in BALB/c mice by a toxi

280 In experimental animals with acute liver failure, we demonstrated beneficial effects

281 lure Study Group registry with indeterminate acute liver failure were analyzed with a similar but mor

282 tes from patients with acetaminophen-induced acute liver failure were assessed for apoptosis-associat

283 nuous renal replacement therapy in pediatric acute liver failure were changed in 2011 following preli

284 Usual causes of acute liver failure were excluded, all drugs were stoppe

285 Children with pediatric acute liver failure were managed according to a set prot

286 ARDS and acute liver failure were more frequent in the Acinetobac

287 ty-eight patients with acetaminophen-induced acute liver failure were recruited.

288 Peak levels in patients with acute liver failure were seen at admission then fell sig

289 responses prevail during the later stages of acute liver failure where elevated levels of M30 are lik

290 evalence of lung injury is relatively low in acute liver failure, where 21% fulfilled acute respirato

291 been implicated in some cases of idiopathic acute liver failure whereas hepatitis G virus does not a

292 ide, viral hepatitis is the leading cause of acute liver failure, whereas acetaminophen hepatotoxicit

293 a greatly enhanced Th1 cytokine response and acute liver failure, which mechanistically depended on T

294 s should be administered to any patient with acute liver failure who develops signs of the systemic i

295 Among children with pediatric acute liver failure who did not receive a liver transpla

296 e acylcarnitine profiles of 27 children with acute liver failure who underwent liver transplantation

297 lar fatty infiltration of hepatocytes causes acute liver failure with coagulopathy and encephalopathy

298 ells to be transplanted intraperitoneally in acute liver failure with the advantage of avoiding immun

299 liver injury (DILI) is an important cause of acute liver failure, with limited therapeutic options.

300 standardize the management of patients with acute liver failure within participating centers.